Consumer Defensive
Comvita New Zealand Ltd.(CVNZF)
Live Price
Offline$0.4161
+0.00% today
1Y Change
-9.31%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $50.00M
- Revenue Growth
- -5.8%
- EPS Growth
- -35.5%
- Dividend Yield
- 0.0%
Coverage: 243 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Comvita New Zealand Ltd. (CVNZF) is a Consumer Defensive stock with a market cap of $50.00M and listed on OTC. The stock last traded around $0.42 and down 9.3% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -5.8%, EPS growth of -35.5%, a dividend yield of 0.0%. What stands out right now is revenue -5.8%, EPS -35.5%, free cash flow +806.9% with operating margin -12.8% and ROIC -19.6%. Valuation is more restrained than many high-expectation growth names at price/sales 0.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CVNZF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Consumer Defensive peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-5.8% vs +1.7% peer median
Operating Margin
Below sector median
-12.8% vs +6.6% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Feb 22, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -5.8% and EPS is at -35.5%, with operating margin around -12.8%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 28, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 22, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Aug 27, 2025 | โ | +0.0% | +0.0% | +0.0% |
2025 Feb 25, 2025 | +10.4% | +0.0% | +0.0% | +0.0% |
Benchmark Edge
CVNZF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CVNZF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CVNZF Max Drawdown
-24.87%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CVNZF and SPY.
Company Overview
Comvita New Zealand Ltd.
OTC
Comvita Ltd. is a renowned company specializing in the production and marketing of natural health products. The firm primarily focuses on leveraging the health benefits of bee-related products, most notably Manuka honey, recognized for its unique anti-bacterial properties. Comvita's product range includes therapeutic and medical goods, skincare items, and natural supplements, which are distributed globally across health stores, pharmacies, and direct online sales. Comvita Ltd. has established itself as a leader in the apiary industry, emphasizing sustainable beekeeping practices and environmental conservation. With its headquarters based in New Zealand, Comvita Ltd. consistently invests in research and development to enhance the efficacy and quality of its offerings, making significant contributions to the natural health sector worldwide.
- Leadership
- Mr. Andy Chen
- Employees
- 400
- Street Address
- 23 Wilson Road South, Paengaroa Private Bag 1 Bay of Plenty
- Mailing
- Te Puke, 3153
- Region
- Te Puke, New Zealand
- Last Updated
- May 9, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.2
- Price/Book
- 0.8
Growth
- Revenue
- -5.8%
- EPS
- -35.5%
- Free Cash Flow
- +806.9%
Profitability
- Gross Margin
- 42.3%
- Operating Margin
- -12.8%
- Net Margin
- -44.5%
- ROE
- -165.5%
- ROIC
- -19.6%
Balance Sheet
- Debt/Equity
- 1.57
- Current Ratio
- 1.80
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.